UCB to comarket Elan Frova
Executive Summary
UCB will contribute 475 primary care sales reps to comarket Elan migraine therapy Frova (frovatriptan) under agreement announced March 28. Companies plan for second quarter 2002 launch. Neurologists will be detailed with Elan and UCB combined sales force of 265 reps under seven-year agreement. Frova was approved Nov. 8 (1"The Pink Sheet" Nov. 12, 2001, p. 35)...
You may also be interested in...
Elan Frova Migraine Launch To Follow Finalized Co-Marketing Agreement
Elan's Frova acute migraine therapy launch awaits finalization of a co-marketing agreement, which is expected to take place by year-end
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.